TEVA.TA
TEVA.TA
IL0006290147
TEVA PHARMA IND
Loading chart...

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Related stocks

TEVA
TEVA • Israel
Teva Pharmaceutical Industries
41.1 USD
47.93B USD 1Y +94.2%
MRK.DE
MRK.DE • Germany
MERCK KGAA I
137.85 EUR
67.16B USD 1Y +13%
ZTS
ZTS • United States
Zoetis Inc.
74.81 USD
30.91B USD 1Y -49.1%
SDZ.SW
SDZ.SW • Switzerland
SANDOZ GROUP N
69.72 CHF
36.35B USD 1Y +40.9%
APN.JO
APN.JO • South Africa
Aspen Pharmacare Hldgs Ltd
15,826 ZAc
4.15B USD 1Y +65.2%
VTRS
VTRS • United States
Viatris Inc.
17.64 USD
20.26B USD 1Y +74.9%
HLN.L
HLN.L • United Kingdom
HALEON PLC ORD GBP0.01
349.2 GBp
40.64B USD 1Y +1%
3692.HK
3692.HK • China
HANSOH PHARMA
31.54 HKD
24.37B USD 1Y -14.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
44.2% p.a.
Max Drawdown (5Y)
-40.5%
Sharpe Ratio (5Y)
0.60
Beta Factor
0.82
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 218%.
🔴 High valuation risk: Avg P/E of 62.8 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (44.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -87.4% in the extended horizon.
ende